Phase I Clinical Trial of the Pharmacokinetics of High-dose Daily Rifapentine, Given as a Single Dose or in Divided Doses to Healthy Volunteers
Latest Information Update: 17 Sep 2021
Price :
$35 *
At a glance
- Drugs Rifapentine (Primary)
- Indications Mycobacterium avium complex infections; Tuberculosis
- Focus Adverse reactions; Pharmacokinetics
- 01 Jun 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 24 May 2013 Planned end date 1 Dec 2013 added as reported by ClinicalTrials.gov.
- 21 May 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.